Jobs

Industry partnership opportunities

The deadlines for these are in April and May.
ASBMB Today Staff
April 1, 2024

The American Society for Biochemistry and Molecular Biology has teamed up with Halo to provide ASBMB members fresh industry partnership opportunities each month. Below you'll find several requests for assistance from companies seeking certain expertise and technologies. Learn more about our partnership with Halo.

Bayer Pharma: Human stem cells from patients with genetically derived cardiomyopathy

Bayer Crop Science is seeking stem cells from patients with dilated cardiomyopathies (e.g. laminopathy or others). The genetic defect in those patients causing the disease should be known. They would also need certain clinical parameters of those patients. The cells are not intending to be used for clinical research and development. The deadline for this opportunity is May 31. Learn more and apply. 

Private company: Unique methods to measure intestinal water and cotransporter regulation

This private company is looking to explore and optimize oral rehydration solutions through the utilization of validated intestinal models. The primary objectives involve evaluating the effects of different solution compositions on intestinal water absorption, solute absorption, and their potential to modulate the activity of co-transporters, particularly those responsible for the transport of sugars and amino acids. The deadline for this opportunity is April 30. Learn more and apply. 

BASF: Biodegradable micro-encapsulation of active ingredients

BASF is seeking a biodegradable encapsulation material for hydrophobic active ingredients. Core-shell morphologies are of high interest, but relevant matrix capsules and other morphologies will be considered. The deadline for this opportunity is April 30. Learn more and apply. 

Private company: Uncovering the “perfect” natural product from a specific bacteria

This private sponsor is seeking partners who can effectively identify natural project actives derived from a proprietary strain. These identified natural products should demonstrate activity against specific pathogens, while not falling under the categories of antibiotics, siderophores, volatile compounds, unstable polyenes or nonribosomally synthesized peptides. The deadline for this opportunity is April 30. Learn more and apply. 

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
ASBMB Today Staff

This article was written by a member or members of the ASBMB Today staff.

Featured jobs

from the ASBMB career center

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Industry

Industry highlights or most popular articles

Strong bonds and a startup
Jobs

Strong bonds and a startup

March 15, 2024

Kevin Lewis’ career path shows that networking is not just about meeting new people to find job leads. Keeping in touch with people from your past can net you opportunities too.

Industry partnership opportunities
Jobs

Industry partnership opportunities

Feb. 27, 2024

The ASBMB has teamed up with Halo to provide ASBMB members fresh industry partnership opportunities each month. The deadline for these is March 31.

Choosing an internship or a fellowship
Jobs

Choosing an internship or a fellowship

Feb. 16, 2024

There are other ways to begin your industry career other than being directly hired to a position. Here we explore the similarities and differences between internships and fellowships in industry.

An academic–industry partnership made possible by Halo
News

An academic–industry partnership made possible by Halo

Jan. 31, 2024

Environmental engineer finds a new use — and new funds — for her lab’s work on a nitrogen-removal system.

Industry partnership opportunities
Jobs

Industry partnership opportunities

Jan. 31, 2024

The ASBMB has teamed up with Halo to provide ASBMB members fresh industry partnership opportunities each month. The deadline for these is Feb. 29.

FDA approves CRISPR–Cas9 therapy for sickle cell disease
News

FDA approves CRISPR–Cas9 therapy for sickle cell disease

Dec. 8, 2023

The gene editing treatment from Vertex Pharmaceuticals and CRISPR Therapeutics is the first of its kind